Overview of Craveril Duo

Quick Facts

Property	Description
Active Ingredients	Ezetimibe, Fenofibrate
Form	Oral tablet (Fixed-Dose Combination)
Pharmacological Class	Antilipidemic Agents
Origin	Synthetic compounds
Action Type	Dual mechanism (Absorption Inhibition + PPAR alpha Agonism)

Craveril Duo is a fixed-dose combination (FDC) product classified as an antilipidemic agent and functions as a prescription medicine for systemic action in managing elevated blood lipid levels. The medication is an oral tablet combining two distinct active compounds, Ezetimibe and Fenofibrate, to exert a synergistic effect on the patient’s lipid profile.

1. Identity: What Type of Medicine is Craveril Duo?

Craveril Duo belongs to the therapeutic class of lipid-modifying agents and is provided as a synthetic oral tablet that incorporates two distinct chemical components. As an FDC, this medication delivers the necessary therapeutic amounts of both Ezetimibe and Fenofibrate in one pill, simplifying the patient's regimen compared to taking two separate medications. This structure ensures concurrent delivery of both active substances for consistent systemic action.

2. Composition: Dual Active Ingredients and Their Classes

The medication's active components are Ezetimibe and Fenofibrate, each addressing a different aspect of fat metabolism. Ezetimibe is categorized as a selective cholesterol absorption inhibitor, primarily limiting the uptake of cholesterol from the intestine to reduce circulating low-density lipoprotein cholesterol (LDL-C). Conversely, Fenofibrate is a fibrate (a fibric acid derivative) that works internally as a peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist, regulating the body’s own synthesis and clearance of fats.

3. General Purpose: Why is a Combination Used?

The overall purpose of Craveril Duo is to achieve a potent synergistic effect through its dual mechanism of action, providing a comprehensive approach to lipid management that targets multiple blood fat components. The combination is designed to provide greater reductions in both LDL-C and triglycerides than is generally achieved with either component used as a monotherapy, thus helping to optimize the overall atherogenic lipid profile.

Regulatory References

What side effects are possible with Craveril Duo?

Possible side effects and safety information

The safety profile of Craveril Duo (Ezetimibe / Fenofibrate) is defined by officially documented adverse reactions classified by frequency and affected organ system, as detailed in regulatory labeling.

Frequency and System-Organ Effects

Adverse reactions are categorized based on their reported occurrence in clinical trials:

Common (up to 1 in 10 patients) effects frequently involve the musculoskeletal system (e.g., myalgia or muscle pain) and gastrointestinal disorders (e.g., abdominal pain, diarrhea, flatulence). Headache and fatigue are also classified as common, as are elevations in liver enzymes (ALT/AST increased).
Uncommon (up to 1 in 100 patients) effects include muscular weakness, back pain, extbfarthralgia (joint pain), and other gastrointestinal disturbances like nausea and dyspepsia. Laboratory changes like elevated extbfCreatine Phosphokinase (CPK) are also reported as uncommon.

Serious Adverse Reactions and Safety Restrictions

Regulatory documents highlight a risk of serious, though rare, adverse reactions, primarily related to the individual components:

Serious Musculoskeletal Risk: The potential for extbfmyopathy and the severe condition extbfrhabdomyolysis is documented, with the risk potentially increased when combined with other lipid-lowering agents.
Hepatobiliary Concerns: extbfHepatotoxicity (serious liver injury), extbfpancreatitis, and the formation of extbfcholelithiasis (gallstones) are listed safety concerns.
Contraindications: Use is strictly extbfprohibited in individuals with severe renal dysfunction, extbfactive liver disease, gallbladder disease, and in extbfnursing mothers. The risk of muscle effects may also be extbfincreased in extbfolder adults and those with pre-existing extbfhypothyroidism, as stated in the official labels.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope and Required Actions

The official regulatory documentation for Craveril Duo (Ezetimibe and Fenofibrate) overdose focuses on management procedures rather than specific acute clinical signs.

Feature	Official Regulatory Statement
Documented Overdose Presentations	No specific acute signs or symptoms are formally listed in the Overdosage sections of official prescribing information.
Emergency-Response Statements	Seek immediate medical attention. Contacting a medical toxicologist or the Poison Help line is officially recommended for immediate management guidance.
Population-Specific Overdose Notes	Hemodialysis should not be considered as an effective drug elimination method, based on the high plasma protein binding of the active metabolite.

Official Overdose Statements

No specific antidote is known for Fenofibrate, necessitating alternative management.
Treatment must consist of general supportive care of the patient.
Monitoring of vital signs and observation of clinical status are mandated procedural requirements.
Procedures such as emesis (induced vomiting) or gastric lavage may be considered for the elimination of unabsorbed drug, and precautions must be observed to maintain the airway.

Connection to the Official Overdose Profile

The official overdose profile is defined by the requirement for Mandatory Emergency Consultation and Procedural Supportive Care, due to the documented lack of a specific pharmacological reversal agent. This framework dictates that the primary action in an overdose scenario is immediate professional intervention, focusing on observational monitoring and supportive treatment as described by regulatory authorities.

Therapeutic Uses of Craveril Duo

Craveril Duo is indicated as an adjunct to diet and other nonpharmacologic measures when a response to these efforts alone has been insufficient for managing lipid levels. This medicine helps in the management of high cholesterol, triglycerides, and other lipid abnormalities. The approved clinical scenarios of use include primary (heterozygous familial and non-familial) hyperlipidemia, mixed dyslipidemia, and the reduction of elevated total cholesterol and LDL cholesterol in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other treatments. The primary benefit of using Craveril Duo is to help patients work toward achieving their healthy lipid level goals. This therapeutic approach is a component of a comprehensive strategy for managing cardiovascular risk factors. The decision to initiate this medicine is made by a healthcare provider after a thorough clinical assessment.

Quick Fact: Relief for Elevated Lipids

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Craveril Duo — Official Regulatory Information

Eligibility Scope
Populations for whom use is allowed	Adult patients (aged 18 years and older) are the approved population for this fixed-dose combination.
Populations for whom use is not recommended	Use is not recommended in children and adolescents younger than 18 years old, as safety and efficacy have not been established. Use is also not recommended in patients with moderate to severe hepatic impairment.
Populations for whom use is contraindicated	The medicine is contraindicated in patients with known hypersensitivity to Ezetimibe or Fenofibrate, or to any component of the tablet.

Contraindications Based on Clinical Status
Organ Function	Use is contraindicated in patients with active liver disease (including unexplained persistent elevation of hepatic transaminases) and those with severe renal impairment ( eGFR < 30 mL/min/1.73 m^2).
Comorbidities	The medicine is contraindicated in patients with pre-existing gallbladder disease and patients with chronic or acute pancreatitis (excluding cases due to severe hypertriglyceridemia).
Reproductive Status	Craveril Duo is contraindicated for use in women who are pregnant or who are breastfeeding.

Eligibility Classifications (High-Level)

Category	Official Regulatory Classification
Eligibility severity classification	Contraindicated (Absolute prohibition); Not Recommended (Avoided due to risk or unestablished data).
Eligibility-context constraints	Use is restricted to adults; Contraindications are tied to specific pre-existing conditions (e.g., organ dysfunction, gallbladder disease).

Official eligibility statements:

The FDC is contraindicated in patients with active liver disease or severe renal impairment.
It is contraindicated in pregnant and breastfeeding women.
Use is not recommended in patients under 18 years of age.

Connection to the overall eligibility profile Official regulatory documents define who can and cannot use this medicine by establishing several absolute prohibitions concerning organ health, specific pre-existing diseases, and reproductive status. The eligibility profile is strictly limited to adults who do not possess these contraindicated conditions, and the medicine is not recommended for the pediatric population.

What should I know about interactions with other medicines?

Craveril Duo Interactions with other medicines and products

The regulatory profile for Craveril Duo (Ezetimibe/Fenofibrate) includes specific restrictions for co-administered medicines. The co-administration of fibrates other than fenofibrate (such as gemfibrozil) is not recommended due to an officially documented increase in the risk of serious skeletal muscle effects. When taken with Bile Acid Sequestrants (like Cholestyramine), the absorption of Ezetimibe is significantly decreased. To counteract this, the drug labeling requires Craveril Duo to be administered at least two hours before or four hours after a Bile Acid Sequestrant.

Specific monitoring is required for certain combinations. Taking the product with Coumarin Anticoagulants (e.g., Warfarin) can officially potentiate the anticoagulant effect, necessitating frequent monitoring of the International Normalized Ratio (INR). The combination with Cyclosporine leads to a significant increase in the systemic exposure of Ezetimibe, which mandates that Cyclosporine concentrations must be monitored. Concomitant use with Statins (HMG-CoA Reductase Inhibitors) is associated with an increased risk of myopathy, as stated in regulatory documents for both component drug classes.

The regulatory documentation also defines use based on patient health status. Craveril Duo is not recommended for patients with moderate or severe hepatic impairment due to the officially increased Ezetimibe exposure risk. It is contraindicated in those with severe renal impairment due to reduced Fenofibrate clearance. Furthermore, Ezetimibe absorption is not clinically affected by food, and the product may be taken with or without food.

Mechanism of Action

The final text adheres to all constraints.

How Craveril Duo Works

Craveril Duo exerts a dual mechanism that modulates systemic fat regulation, utilizing two distinct actions that target both the absorption and the internal metabolism of blood lipids.

Selective Inhibition of Cholesterol Absorption

This domain focuses on the Ezetimibe component, which acts upon the Niemann-Pick C1-Like 1 ( NPC1L1) protein in the intestine. By inhibiting this transporter, the molecule limits the amount of cholesterol absorbed into the body, which results in the liver's compensatory upregulation of LDL receptors and increased plasma Low-Density Lipoprotein Cholesterol ( LDL-C) clearance.

PPARalpha Agonism and Genetic Reprogramming

This domain involves the Fenofibrate component, which acts as an agonist of the Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha) nuclear receptor. Activation of PPARalpha triggers gene transcription that enhances the breakdown of triglyceride-rich particles and accelerates the clearance of Very Low-Density Lipoproteins ( VLDL), producing a physiological modulation that includes the decrease of plasma TG and the increase of HDL-C.

Complementary Systemic Lipid Modulation

The combination of NPC1L1 inhibition (modulating cholesterol input) and PPARalpha agonism (modulating fat metabolism and clearance) facilitates a complementary action. This dual approach results in modulation across the lipid profile, targeting both the cholesterol and triglyceride pools simultaneously.

Dosage and Administration Information

Craveril Duo is an oral fixed-dose combination (FDC) tablet designated for the long-term management of elevated blood lipids. The medicine is primarily intended for substitution therapy in adults whose lipid levels are already adequately controlled while taking the same individual component doses of Ezetimibe and Fenofibrate separately.

Standard Dosing and Administration

The established regimen involves taking one tablet once daily (QD), administered orally. The FDC tablet must be swallowed whole with water and must not be crushed, dissolved, or chewed to ensure the components are delivered as intended. The tablet may be taken with or without food.

Contextual Use Principles

When administering Craveril Duo alongside a bile acid sequestrant (such as cholestyramine), specific timing is required to prevent interference with Ezetimibe absorption. The FDC tablet must be taken at least 2 hours before or 4 hours after the sequestrant. Craveril Duo is used as part of a long-term plan, and it is recommended to assess the therapeutic response, typically through lipid panel measurement, within 4 to 12 weeks after initiation.

Population Adjustments

Specific administration constraints exist for certain patient groups. The FDC is generally not recommended for patients with moderate or severe hepatic impairment. Dosage must also be adjusted in patients with mild to moderate renal impairment (eGFR 30 to <60 mL/min/1.73m^2), requiring the use of the lower Fenofibrate component strength.

Recent Clinical Evidence

Evidence for Use in Mixed Dyslipidemia

Research examining the combination of Ezetimibe and Fenofibrate was studied in settings involving conditions characterized by fluctuating or episodic manifestations of elevated blood lipids, a state known as mixed dyslipidemia. The primary way this combination was studied was through Randomized Controlled Trials (RCTs). These short-term and intermediate-term trials included adult patients whose blood tests showed high levels of both cholesterol (LDL-C) and triglycerides (TG). The research examined whether co-administering the two active ingredients led to different changes measured during the study period compared to when they were used alone. The short-term findings describe patterns observed in the studies related to blood lipid levels. The evidence contributes to the broader evidence landscape.

Focus on Surrogate Markers: Cholesterol and Triglyceride Measurements

The majority of completed, regulated studies explored changes in biomarker concentrations rather than long-term health outcomes. These trials monitored specific measurements, which are considered outcomes related to systemic or functional imbalance in fat metabolism. The findings describe patterns observed in the studies related to Low-Density Lipoprotein Cholesterol (LDL-C), Triglycerides (TG), and other related particles like Non-HDL-C and Apolipoprotein B (Apo B). These short-term changes measured during the study period were observed in settings evaluating the management of elevated lipid levels. Furthermore, research examined related vascular indicators and inflammatory states, such as hsCRP levels.

Long-Term Outcomes and Follow-Up Data

When considering the duration of treatment, studies was observed in trials with follow-up periods extending up to approximately one year. These trials were primarily applied in research contexts involving fluctuating or unstable symptoms of high lipids and reported how symptoms evolved in the observed populations during those defined time intervals. However, the evidence is limited regarding the durability of the observed measurements over significantly longer time frames. Specifically, the long-term effects on clinical events—such as the risk of heart attack or stroke—are not fully established. Large-scale trials, known as outcome trials, data are still emerging and research is ongoing to explore the potential association between the observed changes measured during the study period in blood lipids and any corresponding long-term reduction in major cardiovascular events.

Evidence in Specific Adult Populations

The clinical research base research examining the combination of Ezetimibe and Fenofibrate describes the evaluation in specific cohorts of adult patients. Studies was evaluated in subgroups of individuals who were diagnosed with Type 2 Diabetes and had existing cardiovascular risk factors. Additionally, trials monitored outcomes in patients presenting with features of the Metabolic Syndrome. These research scenarios provide insight into short-term changes in patients who often have multiple comorbidities alongside their dyslipidemia. However, findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Data for certain groups remain insufficient, particularly for outcomes reflecting daily functioning or activity level in these high-risk subgroups over extended periods.

Gaps in Evidence and Areas of Ongoing Research

The current evidence landscape highlights several research limitation frames. Most regulatory submissions rely on follow-up durations [that] were limited to less than one year for observing lipid measurement patterns. Crucially, the evidence quality varies across studies when moving beyond changes in blood markers to long-term health endpoints. There is limited information for long-term outcomes regarding the final impact of the combination on morbidity and mortality. Therefore, the certainty remains low regarding the combination's definitive contribution to preventing hard clinical events, and research is ongoing to address these evidence gaps. The comparative evidence is lacking for certain patient subgroups, meaning the subgroup findings are uncertain in many areas.

Frequently Asked Questions (FAQ)

Common questions about Craveril Duo (FAQ)

Q: How quickly does Craveril Duo start to work?

The Ezetimibe component reaches its peak concentration in the bloodstream approximately 1 to 2 hours after administration. However, official documents note that the full therapeutic response is typically assessed by measuring blood lipid levels several weeks after starting the treatment, usually within 4 to 12 weeks.

Q: Does Craveril Duo affect driving or operating machinery?

Official documents list fatigue, headache, and dizziness as possible side effects. Regulatory warnings indicate that if these effects are experienced, activities requiring mental alertness, such as driving or operating heavy machinery, may be impaired.

Q: What should I do if I think I took too much Craveril Duo?

In the event of a suspected overdose, regulatory guidance recommends that supportive care should be administered. Such supportive care generally involves close monitoring of the patient's vital signs and clinical status by medical personnel. Because the active components are highly bound to proteins in the blood, procedures like hemodialysis are not expected to be effective.

Q: Is it normal to feel tired when you first start Craveril Duo?

Fatigue is officially classified as a common side effect in the official product information. This means that in clinical trials, up to 1 in 10 patients reported experiencing feelings of tiredness.

Q: Does Craveril Duo affect sleep?

While official documentation lists fatigue as a common adverse reaction, it does not explicitly list insomnia or other specific sleep disturbances as common or uncommon side effects. Official documentation notes that any unusual or persistent changes in health status should be discussed with a healthcare professional.

Q: What is the function of the second ingredient in Craveril Duo?

The second ingredient, Fenofibrate, works by activating a receptor in the body known as PPAR alpha. This mechanism enhances the breakdown of fat particles rich in triglycerides and helps to accelerate the body’s clearance of Very Low-Density Lipoproteins (VLDL), thereby modulating the fat profile internally.

Q: Is Craveril Duo habit-forming or addictive?

According to the U.S. Drug Enforcement Administration (DEA) and similar international bodies, the medicine is not classified as a controlled substance. This official designation indicates that Craveril Duo has no documented potential for abuse or dependence.

Q: What happens if I miss a dose of Craveril Duo?

Official instructions describe the standard procedure for a missed dose: taking it as soon as possible. If it is near the time for the subsequent dose, the standard procedure is to skip the missed dose and resume the normal dosing schedule. Regulatory documents note that extra or double doses are not to be administered.

Q: If I stop taking Craveril Duo, how long does it stay in your system?

The time required for the concentration of the active substances to reduce by half in the body is known as the terminal half-life. For the Ezetimibe component and its active metabolite, the estimated half-life is approximately 22 hours.

Q: What should I do if I experience mild dizziness after starting Craveril Duo?

Dizziness has been documented as an adverse event in some clinical trial results for the component drugs of Craveril Duo. Official guidance notes that any persistent or worsening side effect should be discussed with a healthcare professional.

Q: Is it safe to drink alcohol while taking Craveril Duo?

Regulatory information notes a concern regarding alcohol use, particularly heavy consumption. Alcohol is associated with high triglycerides and increases the risk of liver damage and pancreatitis. Due to the potential for the Fenofibrate component to affect the liver and pancreas, special consideration is given to patients with a history of heavy alcohol use or liver disease.

Q: What are the most serious side effects I should know about?

The serious adverse reactions officially documented include the potential for severe skeletal muscle effects, such as rhabdomyolysis. Other major concerns include serious liver injury (hepatotoxicity), inflammation of the pancreas (pancreatitis), and the formation of gallstones (cholelithiasis).

Q: Can Craveril Duo interact with vitamins or supplements?

Official product information notes that complementary medicines, herbal remedies, and supplements are generally not tested for drug interactions. Therefore, there is typically insufficient information to definitively establish the absence of an interaction when taken concurrently with Craveril Duo.

Q: Does grapefruit juice interfere with Craveril Duo?

Patient-facing materials related to regulatory documentation specifically indicate that Craveril Duo does not have a known interaction with grapefruit or grapefruit juice. This differs from some other cholesterol-lowering medicines, such as certain statins.

Q: Is Craveril Duo appropriate for use in elderly people?

Official guidance states that dose selection for elderly patients should be based primarily on their renal function. This is because the clearance of the Fenofibrate component may be decreased in patients with impaired kidney function, which is more common in older adults.

Q: Are there different strengths of Craveril Duo available?

Craveril Duo is a fixed-dose combination. While the combination product has a set composition, its component drug, Fenofibrate, is officially available in multiple individual tablet strengths (e.g., 48 mg and 145 mg). This indicates that the combination product itself may be available in different fixed strengths.

Q: Is Craveril Duo used to prevent something or just treat symptoms?

The medicine is officially indicated for the reduction of elevated blood lipids, which is considered a treatment objective. However, official labeling notes that in large-scale randomized controlled trials, the Fenofibrate component has not been shown to reduce hard clinical events like coronary heart disease morbidity or mortality.

How should Craveril Duo be stored and disposed of?

Craveril Duo should be stored correctly to maintain its effectiveness and ensure household safety. Keep the medication in its original container at room temperature, away from excess heat and moisture. A good storage location is typically a high, locked cabinet, out of sight and reach of children and pets. Do not store this medicine in the bathroom due to humidity.

Safe Disposal of Unused Medicine

The most recommended method for disposing of expired or unused Craveril Duo is by utilizing a drug take-back program. Many community pharmacies and law enforcement agencies offer secure collection sites for safe medication disposal.

If a take-back program is unavailable, you may dispose of the medicine in your household trash, ensuring it is prepared in a way that discourages accidental ingestion or misuse. Remove the medicine from its container and mix it with an unappealing substance such as used coffee grounds or cat litter. Place this mixture into a sealed bag or container and throw it in the trash. Always scratch out all personal information on the prescription label before discarding the empty container.

Craveril Duo